Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant virus encoding one or more heterologous proteins...
Reexamination Certificate
2009-02-26
2011-10-04
Parkin, Jeffrey (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant virus encoding one or more heterologous proteins...
C424S208100, C424S232100
Reexamination Certificate
active
08029800
ABSTRACT:
The invention relates to novel insertion sites useful for the integration of HIV DNA sequences into the MVA genome, and to the resulting recombinant MVA derivatives.
REFERENCES:
patent: 5185146 (1993-02-01), Altenburger
patent: 6596279 (2003-07-01), Paoletti et al.
patent: 6682742 (2004-01-01), Wintersperger et al.
patent: 7501127 (2009-03-01), Howley et al.
patent: 7550147 (2009-06-01), Howley et al.
patent: 2001/0007659 (2001-07-01), Wong-Staal et al.
patent: 0753581 (1997-01-01), None
patent: 1288304 (2003-03-01), None
patent: 1146125 (2004-12-01), None
patent: 97/02355 (1997-01-01), None
patent: 01/68820 (2001-09-01), None
patent: 02/42480 (2002-05-01), None
patent: 03/053463 (2003-07-01), None
patent: 03/097675 (2003-11-01), None
patent: 03/097844 (2003-11-01), None
patent: 03/097845 (2003-11-01), None
patent: 2004/015118 (2004-02-01), None
patent: 2004/048582 (2004-06-01), None
Journal of Virology Instructions to Authors, 2010, J. Virol. 84:17.
Spehner, D., et al., 1990, Construction of fowlpox virus vectors with intergenic insertions: expression of the beta-galactosidase gene and the measles virus fusion gene.
Scheiflinger, F., et al., 1996, Evaluation of the thymidine kinase (tk) locus as an insertion site in the highly attenuated vaccinia MVA strain. Arch. Virol. 141:663-669.
Antoine, G., et al., 1998, The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virol. 244:365-396.
Meyer et al.,Mapping of Delections in the Genome of the Highly Attenuated Vaccinia Virus MVA and Their Influence on Virulence, J Gen Virol., vol. 72 (Pt 5), pp. 1031-1038, (1991).
Francis et al., “Advancing AIDSVAXTm to Phase 3. Safety, Immunogenicity, and Plans for Phase 3,” AIDS Res. Hum. Retroviruses, vol. 14 (Suppl. 3) No. (5), pp. S325-S331 (1998).
Scheiflinger et al., “Evaluation of the Thymidine Kinase (tk) Locus as an Insertion Site in the Highly Attenuated Vaccinia MVA Strain”, Arch Virol., vol. 141 No. (3-4), pp. 663-669, (1996).
Goebel et al., “The Complete DNA Sequence of Vaccinia Virus”, Viroloy, vol. 179 No. (1), pp. 247-266 and 517-563, (1990).
Massung et al., “Analysis of the Complete Genome of Smallpox Variola major Virus Strain Bangladesh-1975”, Virology, vol. 201 No. (2), pp. 215-240, (1994).
Needleman et al., “A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins”, J. MoL Biol,. vol. 48 No. (3), pp. 443-453, (1970).
Davison et al., “Structure of Vaccinia Virus Late promoters”, J. Mot Biol., vol. 210 No. (4), pp. 771-784, (1989).
Agostini et al., “Phosphorylation of Vpr Regulates HIV Type 1 Nuclear Import and Macrophage Infection”, AIDS Res Hum Retroviruses, vol. 18 No. (4), pp. 283-288, (2002).
Vanitharani et al., “HIV-1 Vpr Transactivates LTR-directed Expression Through Sequences Present Within -278 to -176 and increases Virus Replication in Vitro”, Virology, vol. 289 No. (2), pp. 334-342, (2001).
Luo et al., “Molecular Determinants of Nef Function”, J. Biomed Sci., vol. 4 No. (4), pp. 132-138, (1997).
Preusser et al., “Presence of a Helix in Human CD4 Cytoplasmic domain Promotes Binding to HIV-1 Nef Protein”, Biochem Biophys Res Commun., vol. 292 No. (3), pp. 734-740, (2002).
Iwai et al., “Recognition of the High Afifnity Binding Site in Rev-response Element RNA by the Human Immunodeffciency Virus Type-1 rev Protein”, Nucleic Acids Res., vol. 20 No. (24), pp. 6465-6472, (1992).
Sutter et al., “Nonreplicating Vaccinia Vector Efficiently Expresses Recombinant Genes”, Proc Nati Acad Sci., vol. 89 No. (22), pp. 10847-10851, (1992).
Mackett et al., “Vaccinia Virus: A Selectable Eukaryotic Cloning and Expression Vector”, Proc Nati Acad Sci, vol. 79 No. (23), pp. 7415-7419, (1982).
Devereux et al., “A Comprehensive Set of Sequence Analysis Programs for the VAX”, Nucleic Acids Res., vol. 12 No. (Pt 1), pp. 387-395, (1984).
Gribskov et al., “Sigma Factors FromE. Coli, B. Subtilis, Phage SP01, and Phage T4 are Homologous Proteins”, Nucleic Acids Res., vol. 14 No. (16), pp. 6745-6763, (1986).
Yang et al., “The Multimeriziation of Human Immunodeficiency Virus Type I Vif Protein: A Requirement for Vif Function in the Viral Life Cycle”, J. Biol. Chem., vol. 276 No. (7), pp. 4889-4893, (2001).
Khan et al., “Human Immunodeficiency Virus Type 1 Vif Protein is Packaged into the Nucleoprotein Complex Through an Interaction with Viral Genomic RNA”, J. Viarl., vol. 75 No. (16), pp. 7252-7265, (2001).
Mahalingam et al., “Functional Analysis of the Simian Immunodeifciency Virus Vpx Protein: Identification of Packaging Determinants and a Novel Nuclear Targeting Domain”, J. Viral., vol. 75 No. (1), pp. 362-374, (2001).
Bour et al., “The Human Immunodeficiency Virus Type 1 Vpu Protein Specifically Binds to the Cytoplasmic domain of CD4: Implications for the Mechanism of Degradation”, J. Viarl., vol. 69 No. (3), pp. 1510-1520, (1995).
Han et al., “Transactivation of Heterologous Promoters by HIV-1”, Nucleic Acids Res., vol. 19 No. (25), pp. 7225-7229, (1991).
Smith et al., “Comparison of Biosequences”, Adv. Appl. Math 2, pp. 482-489, (1981).
Schwartz et al., “Matrices for Detecting Distant Relationship”, Atlas of Protein Sequences, pp. 353-358, (1979).
Wilson et al., “Development of a DNA Vaccine Designed to Induce Cytotoxic T Lymphocyte Responses to Multiple Conserved Epitopes in HIV-1”, J Immuno., vol. 171 No. (10), pp. 5611-5623, (2003).
Woodberry et al., “Immunogenicity of a Human Immunodeifciency Virus HIV Polytope Vaccine Containing Multiple HLA A2 HIV CD8+ Cytotoxic T-cell Epitopes”, Virology, vol. 73, No. 7, pp. 5320-5325, (1999).
Didierlaurent et al., “Attenuated Poxviruses Expressing a Synthetic HIV Protein Stimulate HLA-A2img id="CUSTOM-CHARACTER-00001" he="2.79mm" wi="3.56mm" file="US08029800-20111004-P00001.TIF" alt="custom character" img-content="character" img-format="tif" ?restricted Cytotoxic T-cell Responses”, Vaccine, vol. 22 No. (25-26), pp. 3395-3403, (2004).
Kmieciak et al., “Enhancement of Cellular and Humoral Immune Responses to Human Immunodeficiency Virus Type 1 Gag and Pol by a G/P-92 Fusion Protein Expressing Highly Immunogenic Gag p17/p24 and Pol p51 Antigens”, Virology, vol. 4, No. (6), pp. 306-316, (2001).
Fang et al., “Expression of Vaccinia E3L and K3L Genes by a Novel Recombinant Canarypox HIV Vaccine Vector Enhances HIV-1 Pseudovirion Production and Inhibits Apoptosis in Human Cells”, Virology, vol. 291, pp. 272-284, (2001).
Antoine et al., “The Complete Genomic Sequence of the Modiifed Vaccinia Ankara Strain: Comparison with Other Orthopoxviruses”, Viorlogy, vol. 244, No. (2), pp. 365-396, (1998).
Spehner et al., Construction of fowlpox virus vectors with intergenic insertions: expression of the beta-galctosidase gene and the measles virus fusion gene, J. Virol. 64(2):527-533 (1990).
Chaplin Paul
Felder Eva
Howley Paul
Leyrer Sonja
Bavarian Nordic A/S
Law Office of Salvatore Arrigo and Scott Lee, LLP
Parkin Jeffrey
LandOfFree
Recombinant modified vaccinia virus ankara (MVA) comprising... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant modified vaccinia virus ankara (MVA) comprising..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant modified vaccinia virus ankara (MVA) comprising... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4272872